TCT-147 High wattage electronic cigarette vaping after coronary stenting induces arterial hypoxemia: a randomized clinical trial
Abstract
Introduction. Propylene glycol (PG) and glycerol (GLY) are the carriers vaporized in electronic cigarette (e-cigarette). Patients with coronary artery disease (CAD) frequently use e-cigarettes as a step to quit tobacco smoking. We demonstrated that e-cigarette vaping induces sustained tissue hypoxia
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
- Comparative effects of e-cigarette smoking on periodontal status, salivary pH, and cotinine levels
- Association between exposure to environmental pollutants and increased oral health risks, a comprehensive review
- Influence of gestational window on offspring vascular health in rodents with in utero exposure to electronic cigarettes
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials
- Nicotine in electronic cigarettes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.